Skip to main content
. 2020 Aug 5;20(4):87. doi: 10.3892/ol.2020.11948

Figure 4.

Figure 4.

Influence of molecular subtypes on the OS of patients with primary breast cancer and with metastatic breast cancer based on the SEER database. (A) OS of 329,770 patients with primary breast cancer by molecular subtype; Log-rank P<0.001. (B) OS of 15,322 patients with metastatic breast cancer by molecular subtype; Log-rank P<0.001. OS, overall survival; SEER, Surveillance, Epidemiology and End Results; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; Cum, cumulative survival. The definition of any censored datapoints: alive that their total time until death could not be determined; or dead of other cause; or missing.